Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck AstraZeneca by Quarter
AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M)
Merck AstraZeneca: $9M in Q2 2026, down 43.7% from a year earlier.
Latest, Q2 2026
9
Period ended Jun 30, 2026
Change on a year earlier
-43.7%
16 in Q2 2025
History
32 quarters
Since Q3 2017
Sources
27
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck AstraZeneca ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-astrazeneca-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.